CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy

Mazzuca, Federica; Botticelli, Andrea; Mazzotti, Eva; La Torre, Marco; Borro, Marina; Marchetti, Luca; Maddalena, Chiara; Gentile, Giovanna; Simmaco, Maurizio; Marchetti, Paolo

doi:10.5152/eurasianjmed.2015.008

CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy

Atıf İçin Kopyala

Mazzuca F., Botticelli A., Mazzotti E., La Torre M., Borro M., Marchetti L., et al.

EURASIAN JOURNAL OF MEDICINE, cilt.48, ss.10-14, 2016 (ESCI İndekslerine Giren Dergi)

Cilt numarası: 48 Konu: 1
Basım Tarihi: 2016
Doi Numarası: 10.5152/eurasianjmed.2015.008
Dergi Adı: EURASIAN JOURNAL OF MEDICINE
Sayfa Sayısı: ss.10-14

Özet

Objective: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes.